Quarterly ResultAug 3, 2026, 02:32 PM
Fresenius Medical Care Q2 Operating Income +23%; Reaffirms FY26 Outlook
AI Summary
Fresenius Medical Care reported strong second-quarter 2026 results, with organic revenue growing 5% and adjusted operating income increasing 23% at constant currency to EUR 569 million. Adjusted earnings per share rose 28% at constant currency to EUR 1.13, supported by the share buyback program. The company made significant progress on its FME Reignite strategy, including the rollout of the 5008X CAREsystem in 227 U.S. clinics and EUR 67 million in savings from the FME25+ program. Fresenius Medical Care reaffirmed its full-year 2026 outlook.
Key Highlights
- Q2 2026 organic revenue grew 5% with growth across all operating segments.
- Q2 2026 operating income (excl. special items) increased 23% (cc) to EUR 569 million.
- Q2 2026 earnings per share (excl. special items) rose 28% (cc) to EUR 1.13.
- 227 U.S. clinics converted to the 5008X CAREsystem, performing over 600,000 treatments.
- FME25+ transformation program delivered EUR 67 million in Q2 savings, targeting EUR 1.2 billion by 2027.
- A second share buyback program for approximately EUR 1 billion was initiated.
- Net leverage ratio remained stable at 2.6x, at the lower end of the target band.
- Company reaffirms its full-year 2026 outlook for revenue and operating income.
Price Impact
More from FMS